Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
22/06/2026 05:34
BRIEF-Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln June 22 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
AND SK BIOPHARMACEUTICALS ENTER AI-POWERED RD COLLABORATION WORTH UP TO $2.5 BILLION
TO RECEIVE UP TO $18 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
TOTAL POTENTIAL DEAL VALUE EXCEEDS $2.5 BILLION INCLUDING MILESTONES AND ROYALTIES
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals Co
See all newsInsilico Medicine hits 3-week high on SK Biopharmaceuticals tie-up
Signs Joint Rd Partnership Agreement With Insilico Medicine
Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
Announces Pharmaceutical Supply Contract